Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

14.10

Mkt cap

1.2B

Volume

949K

High

14.47

P/E Ratio

-8.91

52-wk high

16.99

Low

14.05

Div yield

N/A

52-wk low

8.26

Over the past three months, 6 analysts have evaluated Liquidia (NASDAQ:LQDA), with all ratings being bullish. The average 12-month price target is $28.83, slightly down from the previous $29.33. Key analysts have maintained or lowered their price targets, reflecting cautious optimism. Liquidia faces financial challenges, including a significant revenue decline and negative profitability metrics.

Portfolio Pulse from Benzinga Insights

August 08, 2024 | 12:02 pm

Needham analyst Serge Belanger maintains a Buy rating on Liquidia (NASDAQ:LQDA) but lowers the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:25 am

Liquidia (NASDAQ:LQDA) reported Q2 2024 GAAP EPS of $(0.37), missing the $(0.34) estimate. Sales were $3.659M, missing the $9.451M estimate. Cash and equivalents totaled $133.1M.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:36 am

Five analysts have shared their evaluations of Liquidia (NASDAQ:LQDA) over the past three months, with all ratings being bullish. The average 12-month price target is $29.6, with a high of $32.00 and a low of $28.00. Liquidia faces challenges in revenue growth, net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

July 18, 2024 | 12:07 pm

Needham analyst Serge Belanger reiterates a Buy rating on Liquidia (NASDAQ:LQDA) and maintains a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 9:29 am

Analysts have provided mixed evaluations for Liquidia (NASDAQ:LQDA) over the past three months, with all five analysts maintaining a bullish stance. The average 12-month price target is $28.8, slightly down from the previous average. Liquidia faces financial challenges, including a significant revenue decline and negative profitability metrics.

Portfolio Pulse from Benzinga Insights

June 25, 2024 | 7:00 pm

Oppenheimer analyst Andreas Argyrides has initiated coverage on Liquidia (NASDAQ:LQDA) with a Perform rating.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 5:53 pm

Shares of Science Applications International Corporation (NASDAQ:SAIC) fell 11% following a 9% year-over-year revenue decline in Q1 2025, despite slightly beating revenue estimates and meeting EPS expectations. Other notable stock movements include Microbot Medical Inc. (NASDAQ:MBOT) jumping 92.5% after FDA approval for a clinical trial, and Bio-Path Holdings, Inc. (NASDAQ:BPTH) rising 75% following positive interim results from a Phase 2 study.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 5:56 pm

Liquidia shares are trading higher following a favorable ruling by the U.S. District Court for the District of Delaware, which denied United Therapeutics' request to block the launch of YUTREPIA.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:28 pm

U.S. stocks were mixed on Monday, with the Dow Jones index falling around 100 points. Several stocks saw significant gains, including Stericycle, Inc. (NASDAQ:SRCL) which rose 15% after announcing a $7.2 billion acquisition deal with Waste Management Inc. (NYSE:WM). GameStop Corp. (NYSE:GME) shares jumped 34.5% following a Reddit post by Roaring Kitty. MarineMax, Inc. (NYSE:HZO) surged 27% amid acquisition talks with OneWater Marine Inc. Other notable gainers included Liquidia Corporation (NASDAQ:LQDA), Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 2:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.